Eli Lilly will invest more than $1 billion in India in the coming years to boost manufacturing and supply through local drugmakers, the company said on Monday, as it seeks to tap into skilled workforce to bolster its global manufacturing expansion.

The collaborations aim to increase the availability of Lilly’s key drugs, including those for obesity, diabetes, Alzheimer’s, cancer and autoimmune conditions, the company said.

“We are making significant investments to increase manufacturing and medicine supply capacity around the world,” Patrik Jonsson, president of Lilly International, said, adding, India is a hub for capability building within its global network.

The company, which launched its blockbuster weight-loss drug Mounjaro in India this year, currently does not operate its own ma

See Full Page